9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
21 citations
,
May 2014 in “Toxicological Sciences” Toluene diisocyanate exposure can cause immune sensitization by interacting with proteins in hair follicles and sebaceous glands.
12 citations
,
February 2010 in “Journal of the European Academy of Dermatology and Venereology” Some people with chronic hair loss may have thyroid autoimmunity.
8 citations
,
June 1981 in “Clinica Chimica Acta”
12 citations
,
July 1957 in “Journal of Investigative Dermatology” Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.
7 citations
,
April 1979 in “The Journal of Pediatrics”
January 2023 in “International journal of dermatology, venereology and leprosy sciences” People with alopecia areata have different blood markers that suggest inflammation and immune system issues compared to healthy individuals.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
May 2023 in “The Journal of Immunology” Alopecia areata involves unique activation of certain immune cells.
August 2023 in “Journal of Cosmetic Dermatology” Higher concentration of botulinum toxin A is safe and effective for treating hair loss in men and women.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
August 2025 in “İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi” The method accurately measures vitamin E compounds in capsules.
July 2024 in “Journal of Investigative Dermatology” ITK inhibitors may effectively treat alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
21 citations
,
November 2010 in “Talanta” Researchers developed a reliable method to measure testosterone and epitestosterone in urine for medical and anti-doping use.
61 citations
,
April 2014 in “Radiation Research” RTA 408 cream protects mice from radiation skin damage.
July 2020 in “Benha Medical Journal” People with severe Alopecia Areata have higher levels of TGF-β1, which may play a role in the condition.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
6 citations
,
October 2021 in “Biomedical Research and Therapy” Alopecia areata patients have higher levels of IL-6 and TNF-α.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
October 2025 in “Indian Dermatology Online Journal” 2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
4 citations
,
July 2023 in “Frontiers in Microbiology” HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.
September 2025 in “Journal of Clinical Medicine” Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
March 2014 in “Journal of The American Academy of Dermatology” TNF-a may not be as involved in certain types of hair loss as previously thought.